ArticleClinical, cosmetic and investigational dermatology2025
A Case Report of Necrolytic Migratory Erythema Associated with Glucagonoma.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Necrolytic migratory erythema(NME) is a rare dermatitis usually associated with pancreatic neuroendocrine tumor as a manifestation of glucogonoma syndrome. Over the past five years, NME has been scarcely reported in the literature, with only 8 cases globally. The age range of affected individuals spans from 28 to 62 years, with a mean onset age of 49.4 years. This report presents a 41-year-old male diagnosed with NME secondary to glucagonoma, highlighting the critical need for heightened clinical vigilance in younger NME patients. And NME can mimic other dermatological conditions, leading to potential misdiagnosis and late tumor identification. This case highlights the typical clinical features, aiming to enhance the diagnostic efficiency and accuracy for NME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.